Skip to main content

Advertisement

SpringerLink
Log in

Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?

  • Diagnostic Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

Introduction

Posterior reversible encephalopathy syndrome (PRES) is a clinico-neuroradiological entity, characterized by typical neurological deficits, distinctive magnetic resonance imaging (MRI) features, and a usually benign clinical course. Although frequently seen in association with hypertensive conditions, many other predisposing factors, notably cytotoxic and immunosuppressant drugs have been associated with PRES. The aim of this study was to determine differences in the MR appearance of PRES according to various risk factors.

Methods

Thirty consecutive patients with clinical and MRI findings consistent with PRES were included. We identified 24 patients with hypertension-related conditions, including 14 patients with preeclampsia–eclampsia, and six patients without hypertension, in whom PRES was associated with exposition to neurotoxic substances. Lesion distribution, extent of disease, and number of affected brain regions were compared between patients with PRES with and without hypertension, and patients with PRES with and without preeclampsia–eclampsia, respectively.

Results

No statistically significant differences in distribution of lesions and extent of disease were observed between patients with PRES with or without hypertension, and patients with or without preeclampsia–eclampsia, respectively. The number of affected brain regions was significantly higher in patients with preeclampsia–eclampsia (p = 0.046), and the basal ganglia region was more frequently involved in these patients (p = 0.066).

Conclusion

Apart from a significant higher number of involved brain regions and a tendency for basal ganglia involvement in patients with PRES associated with preeclampsia–eclampsia, the MRI appearance of patients with PRES does not seem to be influenced by predisposing risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500. doi:10.1056/NEJM199602223340803

    Article  PubMed  CAS  Google Scholar 

  2. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, Teksam M (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 189:904–912. doi:10.2214/AJR.07.2024

    Article  PubMed  Google Scholar 

  3. Covarrubias DJ, Luetmer PH, Campeau NG (2002) Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 23:1038–1048

    PubMed  Google Scholar 

  4. Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28:1320–1327. doi:10.3174/ajnr.A0549

    Article  PubMed  CAS  Google Scholar 

  5. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J (2006) Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 27:2179–2190

    PubMed  CAS  Google Scholar 

  6. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G (1998) Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 19:415–417

    PubMed  CAS  Google Scholar 

  7. Russell MT, Nassif AS, Cacayorin ED, Awwad E, Perman W, Dunphy F (2001) Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging 19:129–132. doi:10.1016/S0730-725X(01)00217-X

    Article  PubMed  CAS  Google Scholar 

  8. Kastrup O, Maschke M, Wanke I, Diener HC (2002) Posterior reversible encephalopathy syndrome due to severe hypercalcemia. J Neurol 249:1563–1566. doi:10.1007/s00415-002-0895-x

    Article  PubMed  CAS  Google Scholar 

  9. Ito Y, Niwa H, Iida T, Nagamatsu M, Yasuda T, Yanagi T, Sobue G (1997) Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction. Neurology 49:1174–1175

    PubMed  CAS  Google Scholar 

  10. Strandgaard S, Paulson OB (1984) Cerebral autoregulation. Stroke 15:413–416

    PubMed  CAS  Google Scholar 

  11. Tamaki K, Sadoshima S, Baumbach GL, Iadecola C, Reis DJ, Heistad DD (1984) Evidence that disruption of the blood–brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy. Hypertension 6:I75–I81

    PubMed  CAS  Google Scholar 

  12. Mukherjee P, McKinstry RC (2001) Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-tensor MR imaging. Radiology 219:756–765

    PubMed  CAS  Google Scholar 

  13. Rodgers GM, Taylor RN, Roberts JM (1988) Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 159:908–914

    PubMed  CAS  Google Scholar 

  14. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescent (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576. doi:10.1542/peds.114.2.S2.555

    Article  Google Scholar 

  15. Port JD, Beauchamp NJ Jr (1998) Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics 18:353–367

    PubMed  CAS  Google Scholar 

  16. Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, Gonzalez RG, Koroshetz WJ (1998) Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 51:1369–1376

    PubMed  CAS  Google Scholar 

  17. Jansen O, Krieger D, Krieger S, Sartor K (1996) Cortical hyperintensity on proton density-weighted images: an MR sign of cyclosporine-related encephalopathy. AJNR Am J Neuroradiol 17:337–344

    PubMed  CAS  Google Scholar 

  18. Rangi PS, Partridge WJ, Newlands ES, Waldman AD (2005) Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia. Neuroradiology 47:586–590. doi:10.1007/s00234-005-1376-6

    Article  PubMed  CAS  Google Scholar 

  19. Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, Donadelli R, Remuzzi G (1992) The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 54:775–780. doi:10.1097/00007890-199211000-00002

    Article  PubMed  CAS  Google Scholar 

  20. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G (1986) Cyclosporin-induced endothelial cell injury. Lab Invest 55:455–462

    PubMed  CAS  Google Scholar 

  21. Kochi S, Takanaga H, Matsuo H, Naito M, Tsuruo T, Sawada Y (1999) Effect of cyclosporin A or tacrolimus on the function of blood–brain barrier cells. Eur J Pharmacol 372:287–295. doi:10.1016/S0014-2999(99)00247-2

    Article  PubMed  CAS  Google Scholar 

  22. Kochi S, Takanaga H, Matsuo H, Ohtani H, Naito M, Tsuruo T, Sawada Y (2000) Induction of apoptosis in mouse brain capillary endothelial cells by cyclosporin A and tacrolimus. Life Sci 66:2255–2260. doi:10.1016/S0024-3205(00)00554-3

    Article  PubMed  CAS  Google Scholar 

  23. Marsen TA, Weber F, Egink G, Suckau G, Baldamus CA (1999) Cyclosporin A induces prepro endothelin-1 gene transcription in human endothelial cells. Eur J Pharmacol 379:97–106. doi:10.1016/S0014-2999(99)00447-1

    Article  PubMed  CAS  Google Scholar 

  24. Truwit CL, Denaro CP, Lake JR, DeMarco T (1991) MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol 12:651–659

    PubMed  CAS  Google Scholar 

  25. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110:1042–1049. doi:10.1002/cncr.22921

    Article  PubMed  CAS  Google Scholar 

  26. Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29:1043–1049. doi:10.3174/ajnr.A0929

    Article  PubMed  CAS  Google Scholar 

  27. Horbinski C, Bartynski WS, Carson-Walter E, Hamilton RL, Tan HP, Cheng S (2009) Reversible Encephalopathy after Cardiac Transplantation: Histologic Evidence of Endothelial Activation, T-cell Specific Trafficking, and Vascular Endothelial Growth Factor Expression. AJNR Am J Neuroradiol. doi:10.3174/ajnr.A1311

  28. Schoch HJ, Fischer S, Marti HH (2002) Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 125:2549–2557. doi:10.1093/brain/awf257

    Article  PubMed  Google Scholar 

  29. Bartynski WS, Boardman JF (2008) Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 29:447–455. doi:10.3174/ajnr.A0839

    Article  PubMed  CAS  Google Scholar 

  30. Brubaker LM, Smith JK, Lee YZ, Lin W, Castillo M (2005) Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging. AJNR Am J Neuroradiol 26:825–830

    PubMed  Google Scholar 

  31. Sundgren PC, Edvardsson B, Holtas S (2002) Serial investigation of perfusion disturbances and vasogenic oedema in hypertensive encephalopathy by diffusion and perfusion weighted imaging. Neuroradiology 44:299–304. doi:10.1007/s00234-001-0721-7

    Article  PubMed  CAS  Google Scholar 

  32. Demirtas O, Gelal F, Vidinli BD, Demirtas LO, Uluc E, Baloglu A (2005) Cranial MR imaging with clinical correlation in preeclampsia and eclampsia. Diagn Interv Radiol 11:189–194

    PubMed  Google Scholar 

  33. Schwartz RB, Feske SK, Polak JF, DeGirolami U, Iaia A, Beckner KM, Bravo SM, Klufas RA, Chai RY, Repke JT (2000) Preeclampsia–eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 217:371–376

    PubMed  CAS  Google Scholar 

  34. Watanabe Y, Mitomo M, Tokuda Y, Yoshida K, Choi S, Hosoki T, Ban C (2002) Eclamptic encephalopathy: MRI, including diffusion-weighted images. Neuroradiology 44:981–985. doi:10.1007/s00234-002-0867-y

    Article  PubMed  CAS  Google Scholar 

  35. Servillo G, Striano P, Striano S, Tortora F, Boccella P, De Robertis E, Rossano F, Briganti F, Tufano R (2003) Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients. Intensive Care Med 29:2323–2326. doi:10.1007/s00134-003-1901-1

    Article  PubMed  Google Scholar 

  36. Rappaport VJ, Hirata G, Yap HK, Jordan SC (1990) Anti-vascular endothelial cell antibodies in severe preeclampsia. Am J Obstet Gynecol 162:138–146

    PubMed  CAS  Google Scholar 

  37. Feekes JA, Cassell MD (2006) The vascular supply of the functional compartments of the human striatum. Brain 129:2189–2201. doi:10.1093/brain/awl158

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Christina Mueller-Mang, Thomas Mang & Daniela Prayer

  2. Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Katharina Klein

  3. Department of Neurology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Agnes Pirker

  4. Department of Pediatrics, SMZ-Ost Danube Hospital, Langobardenstrasse, 722, 1220, Vienna, Austria

    Christine Prchla

Authors
  1. Christina Mueller-Mang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Mang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agnes Pirker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katharina Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine Prchla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniela Prayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Mueller-Mang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mueller-Mang, C., Mang, T., Pirker, A. et al. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?. Neuroradiology 51, 373–383 (2009). https://doi.org/10.1007/s00234-009-0504-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-009-0504-0

Keywords

Search

Navigation